Stock quote - Summary

Avacta Group
AVCT: 71.50 0.00 ( 0.00 %) delayed: 16:57PM
Bid price 70.00 High price 71.88
Ask price 73.00 Low price 70.00
Open price 71.50 Spread 4.11%
Prev close 71.50 Volume 10,125

Avacta Group - Share price charts

You need to install or upgrade your Flash Player
Historic - 1 year
You need to install or upgrade your Flash Player

Advanced Avacta Group charts >

Avacta Group - Share price information
Name Avacta Group Epic AVCT
Activities Avacta Group plc (formerly Readybuy plc) is dedicated to providing life scientists with high quality, powerful tools to enable them to work faster and smarter in accelerating our understanding of biology and disease, and to help them apply these advances to diagnosis and treatment. Avacta came to the AIM market in 2006 to provide instrumentation, consumables and reagents for life science researchers. The Group's activities are now focused on Affimer® technology, an engineered alternative to antibodies, which it is commercialising through Avacta Life Sciences. Antibodies are the gold standard affinity reagents used in life sciences and they dominate research, diagnostic, and therapeutic markets worth over $75bn despite their limitations. Antibodies generally have problems with specificity to their target, have very long development times, are limited to certain targets by the need to use animals' immune systems in their development and are expensive to produce. There are also many important applications where antibodies struggle because of the nature of these large, complex and often fragile proteins. 'Affimer' technology is based on a small protein that can be engineered to bind with high specificity and affinity to a wide range of targets. They are generated rapidly in a few weeks without any use of animals and are easily manufactured with high yields. Their simple structure and robust nature makes them able to address applications where antibodies cannot be used, as well as being an alternative to antibodies in a wide range of applications in diagnostics, drug / biomarker discovery, life sciences research & therapeutics. ISIN GB00BYYW9G87
Latest Share Price (p) 71.50 Net Gearing (%) -20.84
Market Capitalisation (pm) 48.91 Gross Gearing (%) 4.52
Shares in issue (m) 68.40 Debt Ratio 0.07
P/E Ratio -10.42 Debt-to-Equity Ratio 0.02
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.05
Dividend Yield (%) 0.00 Price to book value 1.36
Dividend Cover 0.00 ROCE (%) -15.52
Earning per share (p) -6.86 EPS Growth (%) -3,330.00
52-week high / low (p) 103.50 / 61.00 DPS Growth (%) n/a
Avacta Group - Broker views
Date Broker Recommendation Price Old target price New target price Notes
24 Aug finnCap Corporate 200.00 200.00 Reiterates
07 Aug finnCap Corporate 200.00 200.00 Reiterates
30 May finnCap Corporate 200.00 200.00 Reiterates
22 May finnCap Corporate 200.00 200.00 Reiterates
24 Apr finnCap Corporate 200.00 200.00 Reiterates

More Avacta Group broker views >

Avacta Group - Director deals
Date Director Type Volume / Price Trade value
21 Aug 2017 Prof Alastair Smith Buy 33,225 @ 74.50p £24,752.63
05 Jul 2017 Michael Albin In Lieu of Fees/Salary 4,345 @ 86.30p £3,749.74
21 Oct 2016 Dr Mike Owen Buy 7,763 @ 90.00p £6,986.70
08 Jul 2016 Michael Albin Buy 3,393 @ 92.10p £3,124.95
29 Apr 2016 Craig Slater Buy 2,222 @ 112.50p £2,499.75

More Avacta Group director deals >

Risk warning: Remember the price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Click here to read the full warning.

Capita Asset Services is a trading name of Capita IRG Trustees Limited which is authorised and regulated by the Financial Conduct Authority and which is also authorised to conduct cross-border business within the EEA under the provisions of the EU Markets in Financial Instruments Directive. Registered office: The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU. Registered in England and Wales No. 2729260.